MTOR and epilepsy: Furthermore, genetic mutations for a variety of mTOR pathway genes, such as DEPDC5 in epilepsy, suggest sensitivity to mTOR inhibitors, providing evidence that genomic profiling can play a role in patient treatment selection [95].